… ) AND (GLP-1 receptor agonist OR GLP-1 derivative OR liraglutide OR Victoza OR semaglutide
OR dulaglutide OR taspoglutide OR exenatide OR lixisenatide OR albiglutide) AND RCT…

… In the semaglutide cardiovascular outcome trial, the rates of new or worsening
nephropathy were lower in the semaglutide group, but rates of retinopathy complications (vitreous …

… Effect of semaglutide on skin microcirculatory function in obese patients with type 2 diabetes
mellitus[J]. Chinese … Semaglutide can not only improve the glucose and lipid metabolism of …

… risk, and liraglutide and semaglutide resulted in a reduction in cardiovascular risk. Trials …
cardiovascular outcomes trials have shown no link between some DPP-4 inhibitors and CVD in …

… Trial-Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity
sponsored by Novo Nordisk and a trial of pulmonary HTN in diabetes patients sponsored …

… , and the over-reliance on semaglutide will also be … semaglutide, and introduces the
progress of semaglutide in blood glucose reduction, weight loss, and treatment of cardiovascular …

… 网络分析中“Once-weekly semaglutide in adults with overweight or obesity”是2021 年减重…
diabetes-5-year outcomes”为2021 年该领域被引网络中被引用次数最高文献 (179 次);Obesity …

… , dapagliflozin, exenatide, liraglutide and oral semaglutide reduced the incidence of all-cause …
, liraglutide and oral semaglutide can reduce the risk of cardiovascular death events, with …

… Impact of obesity on the metabolic control of type 2 diabetes: results of the Turkish Nationwide
… Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J …

… ꎬ这时对口服制剂的需求就更迫切ꎬ 目前ꎬ Semaglutide的前景较好ꎬ其Ⅱ期临床研究结果显示
ꎬ… therapy in newly diagnosed type 2 diabetic patients with overweight and/ or obese[J]. Curr …